Cancer Therapy

Generex enters collaboration on Ii-suppression technology

Published in Gene Therapy Weekly, November 13th, 2003

Generex Biotechnology Corp.'s (GNBT) Antigen Express subsidiary announced a research collaboration with Transgene, S.A., Strasbourg, France, (TRGNY) to assess the Ii-suppression technology in preclinical cancer models.

Transgene will insert Antigen Express' Ii-suppression gene in its adenovirus-based cancer-immunotherapy products and evaluate the constructs in several animal models. The program is expected to proceed for up to 12 months after which time the companies have agreed to review the data in the view of further collaboration.

Robert E. Humphreys, MD, PhD, founder of Antigen Express, said, "Transgene has recognized expertise in the molecular...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2003-11-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry